Literature DB >> 7517447

Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes.

K Nagase1, K Iwasaki, K Nozaki, K Noda.   

Abstract

The distribution of FK506 in the blood was estimated in-vitro. At a drug level of 5 ng mL-1, FK506 mainly distributed in erythrocytes (95-98%) in dog, monkey and human blood, and its distribution was affected by drug concentration, temperature, and haematocrit values. In erythrocytes most of FK506 was distributed in cytoplasmic components and was bound strongly to a protein having a molecular weight of 10-11 kDa. The molecular weight of this protein agrees with FK506-binding protein found in various cells. Greater than 98.8% of FK506 was bound to the plasma proteins in all species studied. FK506 bound to various plasma proteins such as lipoproteins, globulins, alpha 1-acid glycoprotein and albumin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517447     DOI: 10.1111/j.2042-7158.1994.tb03752.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  25 in total

1.  Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction.

Authors:  Itziar Oteo; John C Lukas; Nerea Leal; Elena Suarez; Andres Valdivieso; Mikel Gastaca; Jorge Ortiz de Urbina; Rosario Calvo
Journal:  Eur J Clin Pharmacol       Date:  2012-06-03       Impact factor: 2.953

2.  Immune responses against islet allografts during tapering of immunosuppression--a pilot study in 5 subjects.

Authors:  V A L Huurman; C R van der Torren; P Gillard; R Hilbrands; E P M W van der Meer-Prins; G Duinkerken; F K Gorus; F H J Claas; B Keymeulen; D L Roelen; D G Pipeleers; B O Roep
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

3.  Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.

Authors:  Wai Johnn Sam; Lai San Tham; Michael J Holmes; Marion Aw; Seng Hock Quak; Kang Hoe Lee; Seng Gee Lim; Krishnan Prabhakaran; Sui Yung Chan; Paul C Ho
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

5.  A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients.

Authors:  Yan-xia Lu; Qing-hong Su; Ke-hua Wu; Yu-peng Ren; Liang Li; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

Review 6.  Immune monitoring post liver transplant.

Authors:  Siddharth Sood; Adam G Testro
Journal:  World J Transplant       Date:  2014-03-24

Review 7.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 8.  Drug interactions with tacrolimus.

Authors:  Teun van Gelder
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 9.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help.

Authors:  S Heidt; D L Roelen; C Eijsink; M Eikmans; C van Kooten; F H J Claas; A Mulder
Journal:  Clin Exp Immunol       Date:  2009-11-18       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.